Table 3.
Univariate analysis and multivariate analysis of pCR predictive factors.
| Variables | N | OR | 95%CI | P | OR | 95%CI | P |
|---|---|---|---|---|---|---|---|
| Sex | |||||||
| Female | 23 | ||||||
| Male | 74 | 0.92 | [0.29,2.87] | 0.88 | |||
| Age | |||||||
| ≦51 | 10 | ||||||
| >51 | 87 | 0.57 | [0.13,2.42] | 0.44 | |||
| PD-1 type, n (%) | |||||||
| Pembrolizumab | 58 | ||||||
| Others | 39 | 0.99 | [0.36,2.70] | 0.98 | |||
| Neoadjuvant cycles, n (%) | |||||||
| ≦2 | 67 | ||||||
| >2 | 30 | 1.26 | [0.45,3.58] | 0.66 | |||
| Chemotherapy regiment | |||||||
| TP regiment | 87 | ||||||
| PF regiment | 10 | 0.40 | [0.047,3.34] | 0.40 | |||
| Time to surgery | |||||||
| ≦45 | 65 | ||||||
| >45 | 32 | 0.44 | [0.133,1.44] | 0.17 | |||
| Pretreatment SII | |||||||
| ≦921.80 | 77 | ||||||
| >921.80 | 20 | 3.61 | [1.22,10.70] | 0.02 | 3.94 | [1.26,12.42] | 0.02 |
| ASAstatus | |||||||
| 2 | 90 | ||||||
| 3 | 7 | 0.62 | [0.07,5.49] | 0.67 | |||
| Smokinghistory | |||||||
| No | 42 | ||||||
| Yes | 55 | 0.92 | [0.34,2.47] | 0.86 | |||
| Dringkinghistory | |||||||
| No | 65 | ||||||
| Yes | 32 | 0.84 | [0.29,2.44] | 0.75 | |||
| Hypertension | |||||||
| No | 79 | ||||||
| Yes | 18 | 1.64 | [0.51,5.31] | 0.41 | |||
| Diabetes | |||||||
| No | 91 | ||||||
| Yes | 6 | 0.76 | [0.08,6.88] | 0.81 | |||
| FEV1202 | |||||||
| ≦2.02 | 24 | ||||||
| >2.02 | 73 | 2.13 | [0.56,8.00] | 0.27 | |||
| LVEF | |||||||
| ≦70.5 | 70 | ||||||
| >70.5 | 27 | 0.39 | [0.10,1.46] | 0.16 | |||
| Tumorlocation | |||||||
| Upper | 9 | ||||||
| Middle third | 49 | 1.01 | [0.18,5.60] | 0.99 | |||
| Lower third | 39 | 0.77 | [0.13,4.50] | 0.77 | |||
| Clinical stage | |||||||
| ≦2 | 40 | ||||||
| >2 | 57 | 0.38 | [0.14,1.04] | 0.06 | 0.35 | [0.12,0.98] | 0.05 |